(504) 309-4948
English Translate into French Translate into German Translate into Spanish Translate into Italian Translate into Japanese Translate into Hindi Translate into Korean Translate into Dutch Translate into Hebrew Translate into Swedish Translate into Chinese (Simplified) Translate into Russian

Giving people back their lives!

HBOT for Cerebral Palsy

Hyperbaric Medicine Officially Enters the Prohibition Era


Hyperbaric Medicine Officially Enters the Prohibition Era

An article specifically written for ”Hyperbaric Medicine Today”
in their “Physicians’ Forum Counterpoint” feature.
From Volume 1 Issue 1
Research in Hyperbaric Medicine by Dr. Eric P. Kindwall

Dr. Paul G Harch writes:

The Physicians' Forum article in the inaugural issue is a comprehensive discourse with many good points on the legality of off-label HBOT, research funding, a registry, recommendations for patients seeking off-label treatment, and standardized testing/documentation. However, these points are nearly lost in an extremely confusing, obfuscating tangle of terms definitions, and concepts that is partly based on a double standard. Despite the confusion, the message and threat to the entire hyperbaric medicine community was transmitted so loud and clear in the final paragraph that I was moved to declare this the “Prohibition Era Of Hyperbaric Medicine” It appears that the purpose of the article is to alter the historical method of the practice of medicine and hyperbaric medicine by jeopardizing a physician's membership in a medical society should they dare to use HBOT for an off-label indication.

The article begins with a comment on “evidence-based medicine”' and then proceeds to speak about peer-reviewed, randomized, prospective, controlled, double-blinded trials (RCPT's) to assess validity of scientific information. The double standard in these two paragraphs can be appreciated in the 1996 approval of intracerebral abscess (ICA), (cerebral abscess, subdural empyema, and epidural empyema) by the Hyperbaric Oxygen Therapy Committee to the accepted indications list. The argument in the 1996 HBOT Committee Report was based on thirteen cases treated off-label, ten of which were published in the Journal of Hyperbaric Medicine, 1989. These were combined with six cases generated after years of open solicitation from an influential HBOT Committee member to any UHMS physician who had treated cerebral abscess with hyperbaric oxygen. These last six cases are strongly biased since very few physicians are willing to volunteer a personal/professional failure, i.e., a hyperbaric oxygen treated cerebral abscess case that died. The mortality from these twenty cases was compared to the latest figures, 1991, on the historical declining mortality rate in cerebral abscess to achieve statistical significance and approve cerebral abscess as an accepted indication. To summarize, the accepted indication, cerebral abscess, is a diagnosis composed of three separate diseases, based on twenty non controlled cases, none of which appear to be on an JRB-approved protocol, all of which were apparently treated off-label, only ten of which are in a peer reviewed journal, six of which are highly biased, non-published solicitations and the argument for which is based on a comparison to a historical declining mortality rate. Regardless of the strong pathophysiological argument this is weak science, especially when compared to data discussed below. To subsequently argue, in the Physicians' Forum article's lead paragraph for evidence-based medicine from randomized prospective controlled research published in peer-reviewed journals as an intro and backdrop to a critique of HBOT/cerebral palsy and off-label use of HBOT, is a double-standard.The article disparages the Hyperbaric Oxygen treatment data of cerebral palsy children by labeling it “anecdotal”

The double standard is more apparent in the article's review of HBOT cerebral palsy data. The article disparages the hyperbaric oxygen treatment data of cerebral palsy children by labeling it "anecdotal." This "anecdotal" experience includes six reports: 240 "anecdotal" cases by Machado, a single "anecdotal" case reported by me in 1994 (the first cerebral palsy case treated with HBOT in North America), three "anecdotal" cases reported by Dr. Neubauer and me at a hyperbaric meeting in Buenos Aires in 1996, an additional "anecdotal" case reported by Neubauer and me in the Third Edition of K.K. Jain 's Textbook of Hyperbaric Medicine in July/99, 18 "anecdotal" predominantly IRB cases reported by me at the Boca Raton July 1999 Conference, and now 25 IRB "anecdotal" cases reported by Montgomery at McGill in 1999. While a number of the above reports are abstracts, three of the studies (Machado, Harch, and Montgomery) are prospective and controlled (each patient serving as his own control). The Montgomery study also used blinded examiners and was published in a peer reviewed journal. This constitutes greater experience for HBOT treatment of cerebral palsy than for the nineteen "anecdotal" HBOT/ICA cases which generated inclusion on the accepted indications list in 1996. To disparage the evidence for HBOT/CP is inconsistent.

Tulane to Host Paul Harch MD HBOT in Cerebral Palsy, Pediatric Brain Injury, Autism and More

Tulane University to Host Paul G. Harch MD Learn What More Than Hope Can Be Done for Cerebral Palsy, Pediatric Brain Injury, Autism, ADHD, ADD, & Learning Disorders

It has long been known that healing many areas of the body cannot take place without appropriate oxygen levels in the tissue.  Most illnesses and injuries occur, and often linger, at the cellular or tissue level.  In many cases, such as: circulatory problems; non-healing wounds; and strokes, adequate oxygen cannot reach the damaged area and the body's natural healing ability is unable to function properly.  Hyperbaric oxygen therapy provides this extra oxygen naturally and with minimal side effects.

Hyperbaric oxygen therapy improves the quality of life of the patient in many areas when standard medicine is not working.  Many conditions such as stroke, cerebral palsy, head injuries, and chronic fatigue have responded favorably to HBOT.

Has your child or do you know someone whose child has been diagnosed with ADHD learning disability or ADD? They’ve been prescribed medication…and your prescription is simply to hope…

Does your child or do you know someone who’s child has cerebral palsy…they’ve had therapy, surgeries…and your asked simply to hope for the best…

The Hyperbaric Chamber: Science, Not Miracle by Nina Subbotina

Nina Subbotina M.D., Ph.D is a specialist in hyperbaric medicine. She is the author of the first scientific book about this specialty written in Spanish: Medicina Hiperbárica.  Here is a first look at her latest book The Hyperbaric Chamber: O2 Science Not Miracle.

Interview with Dr. Paul Harch: The Application of Hyperbaric Oxygen Therapy in Autism and Other Chronic Neurological Conditions

visit www.autismone.orgInterview with Dr. Paul Harch:
The application of hyperbaric oxygen therapy in chronic neurological conditions



Paul G. Harch, MD and Teri Small


As hyperbaric oxygen therapy (HBOT) moves closer to a standard of care for many deemed ‘hopeless’ diseases it still remains a controversial and misunderstood treatment. Currently there are thirteen medical conditions approved for treatment with HBOT. But over twenty-two years of experience has shown Dr. Paul Harch astounding medical benefits when applied to diseases like Cerebral Palsy Autism, Stroke, Traumatic Brain Injury, and many others. This interview explores the science behind these applications. 

Teri Small, from AutismOne Radio, and Dr. Harch talk about HBOT defined as a pharmaceutical and its pharmacologic effects in the application of HBOT to neurology, including autism. 

Harch HBOT in Cerebral Palsy and Pediatric Neurology: A Scientific Perspective

This article will review the current literature and history of application of low pressure (low dosage) LPHBOT to pediatric neurology. The most rigorous study on this subject will be analyzed and its interpretation debated in terms of past and present scientific data and theoretical considerations. The major flaw in the study's conclusion is illustrated by pre and post HBOT SPECT brain imaging on two of the author's cerebral palsy patients and the author's 12-year-experiehce of HBOT treatment of Cerebral Palsy children. There is substantial scientific explanation and data to argue for reimbursement of HBOT in Cerebral Palsy.